Manufacturer record
AMBROSIA PHARMA 91 Indl. Estate: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by AMBROSIA PHARMA 91 Indl. Estate were declared Not of Standard Quality in July 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: AT-110, NEUROSIA (exp Mar 2027). Drug Testing Laboratory Dalgate, Jammu and Kashmir (state lab) found it not of standard quality: Failing in Disintegration Test. Listed in the July 2025 alert.
Records by type
2 records linked to AMBROSIA PHARMA 91 Indl. Estate in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| NEUROSIA | Batch AT-110Mfg Apr 2024 · Exp Mar 2027 | Failing in Disintegration Test.Disintegration | Drug Testing Laboratory Dalgate, Jammu and KashmirState lab | Jul 2025 |
| AMBROSPAS | Batch AT-111Mfg Apr 2024 · Exp Mar 2027 | Failing in Disintegration Test.Disintegration | Drug Testing Laboratory Dalgate, Jammu and KashmirState lab | Jul 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.